Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation

Shady Adnan Awad; Oscar Brück; Naranie Shanmuganathan; Timo Järvinen; Hanna Lähteenmäki; Jay Klievink; Hazem Ibrahim; Soili Kytölä; Perttu Koskenvesa; Timothy P. Hughes; Susan Branford; Matti Kankainen; Satu Mustjoki

doi:10.1038/s41408-022-00667-9

Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation

Shady Adnan Awad, Oscar Brück, Naranie Shanmuganathan, Timo Järvinen, Hanna Lähteenmäki, Jay Klievink, Hazem Ibrahim, Soili Kytölä, Perttu Koskenvesa, Timothy P. Hughes, Susan Branford, Matti Kankainen, Satu Mustjoki

Research output: Contribution to journal › Letter › Scientific

Original language	English
Article number	69
Journal	Blood cancer journal
Volume	12
Issue number	4
Number of pages	4
ISSN	2044-5385
DOIs	https://doi.org/10.1038/s41408-022-00667-9
Publication status	Published - 20 Apr 2022
MoE publication type	B1 Journal article

Fields of Science

CELLS
3111 Biomedicine
3122 Cancers

Access to Document

10.1038/s41408-022-00667-9

s41408-022-00667-9Final published version, 618 KBLicence: CC BY

Cite this

Awad, S. A., Brück, O., Shanmuganathan, N., Järvinen, T., Lähteenmäki, H., Klievink, J., Ibrahim, H., Kytölä, S., Koskenvesa, P., Hughes, T. P., Branford, S., Kankainen, M., & Mustjoki, S. (2022). Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation. Blood cancer journal, 12(4), [69]. https://doi.org/10.1038/s41408-022-00667-9

@article{f92d66c5c0114f1aa6cb2d2184a8a351,

title = "Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation",

keywords = "CELLS, 3111 Biomedicine, 3122 Cancers",

author = "Awad, {Shady Adnan} and Oscar Br{\"u}ck and Naranie Shanmuganathan and Timo J{\"a}rvinen and Hanna L{\"a}hteenm{\"a}ki and Jay Klievink and Hazem Ibrahim and Soili Kyt{\"o}l{\"a} and Perttu Koskenvesa and Hughes, {Timothy P.} and Susan Branford and Matti Kankainen and Satu Mustjoki",

year = "2022",

month = apr,

day = "20",

doi = "10.1038/s41408-022-00667-9",

language = "English",

volume = "12",

journal = "Blood cancer journal",

issn = "2044-5385",

publisher = "Nature Publishing Group",

number = "4",

}

Awad, SA , Brück, O, Shanmuganathan, N, Järvinen, T, Lähteenmäki, H, Klievink, J, Ibrahim, H , Kytölä, S , Koskenvesa, P, Hughes, TP, Branford, S, Kankainen, M & Mustjoki, S 2022, 'Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation', Blood cancer journal, vol. 12, no. 4, 69. https://doi.org/10.1038/s41408-022-00667-9

TY - JOUR

T1 - Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation

AU - Awad, Shady Adnan

AU - Brück, Oscar

AU - Shanmuganathan, Naranie

AU - Järvinen, Timo

AU - Lähteenmäki, Hanna

AU - Klievink, Jay

AU - Ibrahim, Hazem

AU - Kytölä, Soili

AU - Koskenvesa, Perttu

AU - Hughes, Timothy P.

AU - Branford, Susan

AU - Kankainen, Matti

AU - Mustjoki, Satu

PY - 2022/4/20

Y1 - 2022/4/20

KW - CELLS

KW - 3111 Biomedicine

KW - 3122 Cancers

U2 - 10.1038/s41408-022-00667-9

DO - 10.1038/s41408-022-00667-9

M3 - Letter

VL - 12

JO - Blood cancer journal

JF - Blood cancer journal

SN - 2044-5385

IS - 4

M1 - 69

ER -